-
魅影直播 Website
- Ensuring value, access & uptake of innovative medicines & vaccines, now & in the future
Ensuring value, access & uptake of innovative medicines & vaccines, now & in the future
Access to medicines and vaccines in England
The graphic below shows all the different uses (鈥渋ndications鈥�) of medicines and vaccines approved by the European Medicines Agency (EMA), the UK's MHRA equivalent, between 2022 and 2025. The graphic tracks each of these indications through the regulatory and reimbursement processes to see if they are available to NHS patients in England.
魅影直播 position on the government鈥檚 plans to develop a Single National Formulary in England
The 魅影直播 welcomes the government鈥檚 intentions to accelerate equitable adoption of innovative medicines in line with the guidance produced by NICE. Overcoming long-standing barriers to adoption of new medicines that are clinically and cost effective is essential for improving equity of access and patient and NHS outcomes.
Improving access to cancer medicines
Access to innovative cancer medicines transforms lives 鈥� helping patients live longer, healthier lives, supporting earlier recovery, and easing pressure on the NHS. By improving how these treatments are valued, funded, and adopted across the health system, we can deliver faster access for patients, better outcomes for families, and a stronger, more resilient life sciences sector that drives the UK鈥檚 global leadership in cancer innovation.
Transforming lives, raising productivity
A new report from PwC for the 魅影直播 shows that, while the NHS has made progress in recent years, access to medicines in the UK remains poor especially in comparison to other developed countries.
UK medicine pricing
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.
NICE methods and process evolution
NICE continues to evolve its methods and processes for evaluating new medicines. Making changes that support patient access remains a priority for the 魅影直播.
Advanced Therapy Medicinal Products (ATMPs)
Advanced Therapy Medicinal Products (ATMPs) are recognised for their potential to revolutionise the way diseases are treated and to transform patient outcomes.
Patient access to combination therapies
A combination therapy combines two or more individual medicines (components) into a single treatment regimen.
Appropriate prescribing
Prescription medicines are important therapeutic options which can be prescribed in order to prevent, treat or cure diseases and symptoms.
Vaccines
Every year, 2 – 3 million lives are saved across the world because of immunisation and only clean water rivals vaccines at reducing infectious diseases and deaths.
Clinical homecare
Meeting the healthcare challenges of today and tomorrow requires innovative solutions that shift healthcare into the community.
Medicine supply
Managing medicine shortages
Every day millions of patients rely on medicines supplied by the pharmaceutical industry.
Counterfeiting
The manufacture and selling of counterfeit medicines is an issue of increasing concern throughout the world. There are potentially fatal consequences for those who inadvertently take such products.